An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group (GOG) experience

Oliver, Kate

65 - Featured Poster
An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group (GOG) experience

Sunday, March 23, 2014: 12:50 PM

West Exhibit Hall (Tampa Convention Center)

K. E. Oliver¹, W. E. Brady², M. J. Birrer³, D. M. Gershenson⁴, G. Fleming⁵ and J. H. Farley⁶
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, ³Massachusetts General Hospital/Harvard University, Boston, MA, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Chicago Medical Center, Chicago, IL, ⁶St. Joseph's Hospital and Medical Center, Phoenix, AZ

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

65 - Featured Poster
An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group (GOG) experience

65 - Featured Poster An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group (GOG) experience

65 - Featured Poster
An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group (GOG) experience